Discovery and Optimization of Novel Constrained Pyrrolopyridone BET Family Inhibitors

Abstract Novel conformationally constrained BET bromodomain inhibitors have been developed. These inhibitors were optimized in two similar, yet distinct chemical series, the 6-methyl-1 H -pyrrolo[2,3- c ]pyridin-7(6 H )-ones (A) and the 1-methyl-1 H -pyrrolo[2,3- c ]pyridin-7(6 H )-ones (B). Each series demonstrated excellent activity in binding and cellular assays, and lead compounds from each series demonstrated significant efficacy in in vivo tumor xenograft models.